Home

Press Releases

About

Editorial

Advertise

Cookie Policy

Privacy

Contact

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

SUBSCRIBE

Market Reports

FDA

Executives

Funding

Non Profits

Hospitals

Acquisitions

Health

Biotechnology News Magazine

Neoss Launches NeoGenix XP™

Safe and Clinically Proven Natural Bone Substitute

Following the successful and well-received Allograft line, Neoss is excited to announce the addition of NeoGenix XP™ this autumn to our existing product portfolio.

NeoGenix XP™ is a safe and clinically proven natural bone substitute, that closer resembles natural bone than those of synthetic materials, such as hydroxyapatite or tricalcium phosphate.

Surface roughness affects cellular response, enhancing cell adhesion and proliferation and possibly other markers of expression of cell phenotype, like production of collagen type I, osteocalcin, extracellular matrix, and mineralized material.

“Being a strong partner to our customers has always been important and offering more in terms of total package solutions. NeoGenix XP™ is an important addition to this and strengthens not only the bone regeneration portfolio but will allow us to serve our customer even better!” —Dr Robert Gottlander, Neoss CEO

This exciting product line will add new dimensions to Neoss existing Bone Regeneration offering, providing an enhanced offering of Bone materials and membranes.

Neoss maintains its clear focus on innovation and has a continuous plan of new market leading product solutions that will be presented over the next few years. All with the same target of introducing smart products that are intuitively easy to use with Intelligent Simplicity.

More here.

 

SourceNeoss®

By using this website you agree to accept Medical Device News Magazine Privacy Policy